Sanofi’s lunsekimig meets goals in asthma, nasal polyps studies

Sanofi announced that its experimental drug lunsekimig met primary and key secondary endpoints in two Phase 2 studies for respiratory diseases, specifically moderate-to-severe asthma and chronic rhinosinusitis with nasal polyps. While the drug showed promise in these areas, an exploratory Phase 2b study for moderate-to-severe atopic dermatitis did not meet its primary endpoint. Lunsekimig is a bispecific antibody targeting TSLP and IL-13, and is currently undergoing further clinical development.